ÂÜÀòÂÒÂ×

Peter Barrett is a partner at Atlas Venture and focuses on investments in therapeutics that significantly improve patient’s quality of life. At Atlas, Dr. Barrett has been involved in the creation of several novel therapeutic and drug discovery platform companies. He is currently chairman of Synlogic and serves on the board of Obsidian Therapeutics and Larimar Therapeutics. Prior to joining Atlas in 2002, Peter was Co-Founder, Executive Vice President, and Chief Business Officer of Celera Genomics. Dr. Barrett helped launch Celera as a publicly traded entity in 1999. He led Celera’s strategic alliances and acquisitions and participated in raising nearly $1 billion in capital for the company. Prior to Celera, he held senior management positions at PerkinElmer, most recently serving as Vice President, Corporate Planning and Business Development. During his tenure, he expanded the life science business units through a series of licensing agreements, partnerships, and acquisitions. Dr. Barrett is currently Vice Chairman of the advisory council of the Barnett Institute of Chemical and Biological Analysis at Northeastern University, as well as an adjunct professor at the Barnett Institute. He also serves on the Board of PerkinElmer. He received a B.S. in chemistry from Lowell Technological Institute (now known as the University of Massachusetts, Lowell), and a Ph.D. in analytical chemistry from Northeastern University. He also completed Harvard Business School’s Management Development Program. Outside the office, Dr. Barrett is a skier, competitive sailor, theater lover, and frustrated actor.